Abstract

Background and Aims: Gastrointestinal (GI) symptoms are frequently observed in coronavirus disease (COVID-19) symptoms. Previous studies have mainly focused on epidemiology and characteristics in patients with GI symptoms, little is known about the roles of the immune response in susceptibility to and severity of infection. Here, we analyzed COVID-19 cases to determine immune response and clinical characteristics in COVID-19 patients with GI symptoms.Methods: Based on the presence of GI symptoms, 79 patients in Xuzhou were divided into GI and non-GI groups. A retrospective study investigating the clinical characteristics, selected laboratory abnormalities, immune response, treatment, and clinical outcome was performed to compare patients with or without GI symptoms.Results: Approximately 25% of patients reported at least one GI symptom. Our results showed significantly higher rates of fatigue, increased LDH, increased CK, higher percentage increase neutrophil-to-lymphocyte ratio (NLR), lymphopenia, and bilateral pneumonia in patients with GI symptoms. No significant changes in serum amylase (SAA), immunoglobulin (Ig) G, IgM, C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6), viral shedding time, liver injury, and kidney injury between the two groups were observed. The clinical type on admission of patients with GI symptoms reported significantly higher rates of critical disease type (20 vs. 3.3%; p = 0.033). However, the survival rate did not differ between the two groups.Conclusions: Increase in total lymphocytes and NLR as well as the elevation of CRP, SAA, PCT, IL-6, CK, and LDH were closely associated with COVID-19 with GI symptoms, implying reliable indicators COVID-19 patients with GI symptoms were more likely to develop into a severe disease.

Highlights

  • The coronavirus disease 2019 (COVID-19) outbreak started in December 2019 in China has spread sharply all over the world [1]

  • We enrolled a total of 79 patients with COVID-19 following the Declaration of Helsinki, which was confirmed by detecting SARS-CoV-2 RNA in throat swab samples using a SARS-CoV-2 nucleic acid detection kit according to the manufacturer’s protocol (Shanghai BioGerm Medical Biotechnology Co.,Ltd)

  • A total of 79 patients with confirmed COVID-19 were enrolled from 26 January 2020 to 16 February 2020 in Xuzhou, among which 20 (25%) patients presented at least one GI tract symptom GI symptoms were as follows: 14 patients experienced diarrhea six patients had vomiting symptoms

Read more

Summary

Introduction

The coronavirus disease 2019 (COVID-19) outbreak started in December 2019 in China has spread sharply all over the world [1]. The epidemiological, clinical dynamic profile among observed in patients with COVID-19 with GI symptoms has begun to emerge [4,5,6], but the characteristics of the immune response in COVID-19 patients with GI symptoms are still not clear. An immune response in COVID-19 patients with GI symptoms is urgently needed to guide clinical diagnosis, treatment, infection control, and vaccine design. The testing of SARS-CoV2 IgG and IgM antibodies helps to diagnose COVID19, and helps to assess the infection status. Previous studies have mainly focused on epidemiology and characteristics in patients with GI symptoms, little is known about the roles of the immune response in susceptibility to and severity of infection. We analyzed COVID-19 cases to determine immune response and clinical characteristics in COVID-19 patients with GI symptoms

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call